The anti-cancer agent nemorosone is a new potent protonophoric mitochondrial uncoupler

Gilberto L Pardo-Andreu1, Yanier Nuñez-Figueredo, Valeria G Tudella

  • 1Centro de Estudio para las Investigaciones y Evaluaciones Biológicas, Instituto de Farmacia y Alimentos, Universidad de La Habana, La Lisa, Ciudad Habana, Cuba. gilbertopardo@infomed.sld.cu

Mitochondrion
|November 4, 2010
PubMed

Insights

Nemorosone, a natural compound, shows potent anti-cancer effects by disrupting cancer cell mitochondria. This mitochondrial uncoupling activity, leading to ATP depletion, is key to nemorosone

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Nemorosone is a natural polycyclic polyprenylated acylphloroglucinol with demonstrated in vitro anti-cancer activity.
  • Understanding the mechanism of action is crucial for its therapeutic development.

Purpose of the Study:

  • To investigate the toxic effects of nemorosone on HepG2 cancer cells.
  • To elucidate the role of mitochondrial function in nemorosone-induced cytotoxicity.

Main Methods:

  • MTT assay to assess cell viability.
  • Measurement of mitochondrial membrane potential and ATP levels.
  • Studies on isolated rat liver mitochondria to evaluate protonophoric and uncoupling activities.
  • Assessment of calcium release, uptake, and mitochondrial swelling.

Main Results:

  • Nemorosone exhibited dose-dependent toxicity on HepG2 cells.
  • It caused mitochondrial membrane potential dissipation and ATP depletion in cancer cells.
  • Nemorosone acted as a potent protonophoric mitochondrial uncoupler, comparable to CCCP, affecting respiration, calcium handling, and inducing mitochondrial swelling and permeability transition.

Conclusions:

  • Nemorosone is identified as a novel and potent protonophoric mitochondrial uncoupler.
  • This mitochondrial uncoupling property is strongly implicated in its observed toxicity towards cancer cells.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...